LLY

1,030.06

+0.68%↑

JNJ

243.75

+1.91%↑

ABBV

224.33

+1.19%↑

NVS

160.78

+0.8%↑

MRK

120.94

+2.06%↑

LLY

1,030.06

+0.68%↑

JNJ

243.75

+1.91%↑

ABBV

224.33

+1.19%↑

NVS

160.78

+0.8%↑

MRK

120.94

+2.06%↑

LLY

1,030.06

+0.68%↑

JNJ

243.75

+1.91%↑

ABBV

224.33

+1.19%↑

NVS

160.78

+0.8%↑

MRK

120.94

+2.06%↑

LLY

1,030.06

+0.68%↑

JNJ

243.75

+1.91%↑

ABBV

224.33

+1.19%↑

NVS

160.78

+0.8%↑

MRK

120.94

+2.06%↑

LLY

1,030.06

+0.68%↑

JNJ

243.75

+1.91%↑

ABBV

224.33

+1.19%↑

NVS

160.78

+0.8%↑

MRK

120.94

+2.06%↑

Search

Pacira Pharmaceuticals Inc-DE

Avatud

SektorTervishoid

21.91 2.62

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

21.38

Max

22

Põhinäitajad

By Trading Economics

Sissetulek

10M

5.4M

Müük

-1.6M

180M

P/E

Sektori keskmine

44.83

121.746

Kasumimarginaal

3.026

Töötajad

788

EBITDA

5.1M

34M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+43.95% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

26. veebr 2026

Turustatistika

By TradingEconomics

Turukapital

-91M

906M

Eelmine avamishind

19.29

Eelmine sulgemishind

21.91

Uudiste sentiment

By Acuity

100%

0%

341 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Pacira Pharmaceuticals Inc-DE Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. apr 2025, 23:45 UTC

Kuumad aktsiad

Stocks to Watch: CVS Health, UnitedHealth Group, Spire Global, Pacira BioSciences

Võrdlus sarnastega

Hinnamuutus

Pacira Pharmaceuticals Inc-DE Prognoos

Hinnasiht

By TipRanks

43.95% tõus

12 kuu keskmine prognoos

Keskmine 30.33 USD  43.95%

Kõrge 38 USD

Madal 23 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Pacira Pharmaceuticals Inc-DE 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

4

Osta

1

Hoia

1

Müü

Tehniline skoor

By Trading Central

24.83 / 26.38Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Weak Bullish Evidence

Sentiment

By Acuity

341 / 352 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Pacira Pharmaceuticals Inc-DE

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
help-icon Live chat